|Bid||43.15 x 800|
|Ask||51.33 x 1000|
|Day's Range||43.95 - 47.95|
|52 Week Range||39.41 - 127.97|
|Beta (5Y Monthly)||0.96|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 07, 2022 - Nov 11, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||66.33|
Subscribe to Yahoo Finance Plus to view Fair Value for NVRO
Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in Q2, partly owing to robust domestic performance.
Nevro (NVRO) delivered earnings and revenue surprises of 12.35% and 0.43%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Nevro Corp. (NYSE: NVRO), delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its financial results for the second quarter ended June 30, 2022, provided guidance for the third quarter of 2022 and updated its full-year 2022 guidance.